Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Grant & Licensing Opportunities In Brief

This article was originally published in The Gray Sheet

Executive Summary

NCI shortage will not affect grants: National Cancer Institute funding of research project grants (RPG) will increase slightly and remain at 46% ($2.2 bil.) of overall budget, despite funding deficit in fiscal 2005. Although the NIH institute technically received a 1.8% budget increase in FY 2005, NCI has $62 mil. less than FY 2004 largely due to continuing RPG obligations, the agency stresses in the Jan. 18 NCI Cancer Bulletin. Reductions will take place outside of RPGs, training, cooperative research groups and specialized programs of research excellence. NCI's Board of Scientific Advisors, Board of Scientific Counselors and National Cancer Advisory Board are discussing how best to manage the remaining funds and how to continue to support new research...

You may also be interested in...



Delcath Systems

National Cancer Institute Phase II study of the firm's catheter-based perfusion technology to deliver the chemotherapy drug melphalan will begin "shortly" to treat primary hepatic tumors and metastatic liver cancer originating from adenocarcinoma, neuro-endocrine or melanoma cancers. Data from 18 patients in the Phase I NCI study showed that more aggressive melphalan treatment is possible using the local delivery technique. Anti-tumor activity was achieved in 75%, or six of eight subjects with inoperable metastatic liver cancers that began as ocular melanoma, Delcath says...

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel